# CD96

Source: https://onco.cc/targets/cd96/  
OnCo record `cd96` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

CD96 sits on T and NK cells and binds CD155, the same molecule TIGIT reads on tumour cells. It is the least tested of that family; one blocking antibody is in phase 2 platform trials in lung cancer.

## Summary

CD96 (chromosome 3q13.13) may mediate adhesive interactions of activated T and NK cells in the late phase of the immune response, promoting NK-cell adhesion to targets through PVR (CD155) on the target cell; it is expressed on normal T-cell lines and clones and at very low levels on activated B cells (UniProt P40200). CD155 is the ligand for the co-stimulatory receptor CD226 and the co-inhibitory receptors TIGIT and CD96 (Kučan Brlić et al. 2017). GSK6097608, an anti-CD96 antibody, is being tested in phase 2 platform studies with dostarlimab in non-small-cell lung cancer (NCT05565378, NCT03739710).

## Fields

- Kind: Target
- Last checked: 2026-09-24
- Also known as: TACTILE; CD96 molecule; T-cell surface protein tactile
- Tags: checkpoint-map
- Symbol: CD96
- Class: checkpoint
- Biology: An immunoglobulin-superfamily receptor of the TIGIT/CD226 axis competing for CD155.
- Where found: T cells and NK cells (UniProt P40200); Non-small-cell lung cancer platform trials of GSK6097608

## Notes

- Prevalence not recorded: HGNC and UniProt carry no positivity rates.

## Sources

- HGNC HGNC:16892: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:16892
- UniProt P40200: https://www.uniprot.org/uniprotkb/P40200/entry
- NCBI Gene 10225: https://www.ncbi.nlm.nih.gov/gene/10225
- ClinicalTrials.gov NCT05565378: https://clinicaltrials.gov/study/NCT05565378

## Connected records

- targets: [CD155 (PVR)](https://onco.cc/targets/pvr/), [TIGIT](https://onco.cc/targets/tigit/)
- drugs: [Dostarlimab](https://onco.cc/drugs/dostarlimab/)
- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [TIGIT blockade](https://onco.cc/technologies/tigit-blockade/)
- pathways: [The cancer-immunity cycle](https://onco.cc/pathways/cancer-immunity-cycle/)
- terms: [Checkpoint (two meanings)](https://onco.cc/terms/checkpoint/)

---
JSON: https://onco.cc/api/v1/entities/cd96.json